Pfizer Inc

PFE-N

NYSE:PFE

40.80
1.39 (3.53%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
SELL
SELL
November 23, 2020
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology program back in June that impacted the long term growth rate going forward.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 23, 2020
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology program back in June that impacted the long term growth rate going forward.
DON'T BUY
DON'T BUY
November 19, 2020
The positive vaccine news helped the stock rally but it has since given up the gains. There is not as much growth as you would like, and pay 13x earnings. Likes other names that has better growth. It has been moving sideways. The only reason to own it is for the dividend.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 19, 2020
The positive vaccine news helped the stock rally but it has since given up the gains. There is not as much growth as you would like, and pay 13x earnings. Likes other names that has better growth. It has been moving sideways. The only reason to own it is for the dividend.
BUY
BUY
October 27, 2020
Allan Tong’s Discover Picks The divvy pays nearly 4%. Investors are already pushing up the Pfizer stock near 52-week highs and price target, both $41, though it trades at a PE of only 14.9x. Currently, one analyst rates Pfizer stock a strong buy, 11 more a buy, nine a hold, and one a sell, its strongest recommendations so far this year. It's a strong company, but upside may be limited. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 27, 2020
Allan Tong’s Discover Picks The divvy pays nearly 4%. Investors are already pushing up the Pfizer stock near 52-week highs and price target, both $41, though it trades at a PE of only 14.9x. Currently, one analyst rates Pfizer stock a strong buy, 11 more a buy, nine a hold, and one a sell, its strongest recommendations so far this year. It's a strong company, but upside may be limited. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
COMMENT
COMMENT
October 20, 2020
Tough to analyze now. He's awaiting their drug test results. They're in the middle of spinning off long-life assets, including Viagra (later this year or next). This spinning-off will transform Pfizer from boring long-life assets to focus on R&D drugs. He expects their Covid vaccine to succeed the first. The CEO issued an update Friday and the testing data so far looks promising. There haven't been any adverse test results yet. He expects data in 2-5 weeks. He's closely watching this. Their Covid vaccine will be a catalyst short-term.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 20, 2020
Tough to analyze now. He's awaiting their drug test results. They're in the middle of spinning off long-life assets, including Viagra (later this year or next). This spinning-off will transform Pfizer from boring long-life assets to focus on R&D drugs. He expects their Covid vaccine to succeed the first. The CEO issued an update Friday and the testing data so far looks promising. There haven't been any adverse test results yet. He expects data in 2-5 weeks. He's closely watching this. Their Covid vaccine will be a catalyst short-term.
DON'T BUY
DON'T BUY
October 14, 2020
Likes healthcare because of demographics, but not her preference. In the process of building up their pipeline. Revenue portfolio will have another period of patent expiration. Wants to see more visibility on the pipeline, or perhaps an acquisition.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 14, 2020
Likes healthcare because of demographics, but not her preference. In the process of building up their pipeline. Revenue portfolio will have another period of patent expiration. Wants to see more visibility on the pipeline, or perhaps an acquisition.
TOP PICK
TOP PICK
September 24, 2020
Stochchase Research Editor: Michael O'Reilly PFE is a defensive Top Pick that pays a strong yield, with history of dividend growth and a strong balance sheet. It is one of the world's leading pharmaceutical companies with a robust pipeline of new products in development (targeting 25 new drugs to market by 2025). They are partnering to develop a COVID-19 vaccine that is now in stage 2/3 testing and has a contract with the US government for $1.95 billion for the first 100 million doses if successful. The company holds $1.8 billion in cash reserves. The yield is strong and is supported with a 58% payout ratio. We would buy this using a $31 stop-loss, looking for a return towards $42. Yield 4.22% (Analysts’ price target is $41.79)
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 24, 2020
Stochchase Research Editor: Michael O'Reilly PFE is a defensive Top Pick that pays a strong yield, with history of dividend growth and a strong balance sheet. It is one of the world's leading pharmaceutical companies with a robust pipeline of new products in development (targeting 25 new drugs to market by 2025). They are partnering to develop a COVID-19 vaccine that is now in stage 2/3 testing and has a contract with the US government for $1.95 billion for the first 100 million doses if successful. The company holds $1.8 billion in cash reserves. The yield is strong and is supported with a 58% payout ratio. We would buy this using a $31 stop-loss, looking for a return towards $42. Yield 4.22% (Analysts’ price target is $41.79)
DON'T BUY
DON'T BUY
September 15, 2020
Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 15, 2020
Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.
DON'T BUY
DON'T BUY
September 14, 2020
It's a bond with drugs. It doesn't have the pipeline of drugs to attract investors.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 14, 2020
It's a bond with drugs. It doesn't have the pipeline of drugs to attract investors.
BUY
BUY
September 4, 2020
One of the largest pharma companies in the world. They have done a good job rebuilding their pipeline of drugs. It's now better built with constant new products. They took a hit due to a cancer drug that didn't prove itself. You get a nice dividend. In the medical space, there are other names like Boston Scientific that could be a good alternative.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 4, 2020
One of the largest pharma companies in the world. They have done a good job rebuilding their pipeline of drugs. It's now better built with constant new products. They took a hit due to a cancer drug that didn't prove itself. You get a nice dividend. In the medical space, there are other names like Boston Scientific that could be a good alternative.
SELL
SELL
August 27, 2020

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 27, 2020

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

PAST TOP PICK
PAST TOP PICK
August 24, 2020
(A Top Pick Sep 16/19, Down 9%) He bought it for stability and the dividend. They have new drugs, including a COVID one. Pays a solid 3.8% dividend. Not worried about this.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 24, 2020
(A Top Pick Sep 16/19, Down 9%) He bought it for stability and the dividend. They have new drugs, including a COVID one. Pays a solid 3.8% dividend. Not worried about this.
BUY
BUY
July 21, 2020
Trades at 14x PE and pays almost a 4% dividend. Tailwind is them working on a COVID-19 vaccine, like all its peers. They have a strong backlog of drugs that will come to market. No headwinds politically which is good.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
July 21, 2020
Trades at 14x PE and pays almost a 4% dividend. Tailwind is them working on a COVID-19 vaccine, like all its peers. They have a strong backlog of drugs that will come to market. No headwinds politically which is good.
DON'T BUY
DON'T BUY
July 16, 2020

Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
July 16, 2020

Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

DON'T BUY
DON'T BUY
July 9, 2020

Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
July 9, 2020

Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.

COMMENT
COMMENT
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Showing 1 to 15 of 691 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 10

Total Signals / Votes : 17

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 17 stock analysts published opinions about PFE-N. 6 analysts recommended to BUY the stock. 10 analysts recommended to SELL the stock. The latest stock analyst recommendation is SELL. Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by Jamie Murray on 2020-11-23. Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

17 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2020-12-02, Pfizer Inc (PFE-N) stock closed at a price of $40.8.